Oculis (OCS) and The Competition Critical Survey

Oculis (NASDAQ:OCS) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Oculis to related companies based on the strength of its dividends, profitability, institutional ownership, risk, earnings, valuation and analyst recommendations.

Earnings and Valuation

This table compares Oculis and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oculis	$1.45 million	-$119.44 million	-4.38
Oculis Competitors	$5.32 billion	$3.20 billion	555.09

Oculis’ peers have higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Oculis has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Oculis’ peers have a beta of -3.71, suggesting that their average stock price is 471% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Oculis and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1	0	9	0	2.80
Oculis Competitors	7798	13889	25783	1038	2.41

Oculis presently has a consensus target price of $38.89, indicating a potential upside of 419.21%. As a group, “Pharmaceuticals” companies have a potential upside of 24.42%. Given Oculis’ stronger consensus rating and higher probable upside, equities analysts clearly believe Oculis is more favorable than its peers.

Profitability

This table compares Oculis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oculis	-8,613.92%	-39.24%	-33.45%
Oculis Competitors	-2,380.39%	-218.78%	-15.59%

Insider & Institutional Ownership

22.3% of Oculis shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Oculis peers beat Oculis on 8 of the 13 factors compared.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.